Compare Nuwellis Inc (NUWE) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Nuwellis Inc trades at $0.68 (market cap $2.20M), while iShares Broad USD Investment Grade Corporate Bond trades at $48.71 (market cap $17.48B). The key difference: iShares Broad USD Investment Grade Corporate Bond is far larger — about 7945.5× Nuwellis Inc's market cap, and Nuwellis Inc is more actively traded (121,544 versus 2,226,889). Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and iShares Broad USD Investment Grade Corporate Bond for 44 Days on average.
| NUWE | USIG | |
|---|---|---|
Market Cap | $2.20M | $17.48B |
Volume | 121,544 | 2,226,889 |
Sector | Health | Fixed Income |
52-Week High | $146.65 | $52.69 |
52-Week Low | $0.68 | $48.54 |
Typical Hold Time | 26 Days | 44 Days |
Enterprise Value | -$1.52M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
USIG trades at $48.68 with minimal daily movement (+0.06%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The stock faces resistance at $49 and support at $48. Recent institutional activity includes Blue Edge Capital's new $21.9 million position and Bank of New York Mellon increasing its stake by 0.9%.
The outlook remains cautious due to bearish technical signals and lack of fundamental data. Investment opportunities include potential support at $48 and institutional accumulation. Key risks involve market volatility and absence of current financial metrics. Investors should await updated earnings reports for fundamental clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
